Evommune公布Evo301治疗中重度特应性皮炎二期a期概念验证试验积极顶线数据

美股速递
Feb 10

生物制药公司Evommune近日宣布,其研发的候选药物Evo301在中重度特应性皮炎患者中开展的二期a期概念验证试验获得积极顶线结果。

该试验数据表明Evo301在主要疗效终点上表现出显著改善,验证了其治疗潜力。这项突破为后续临床开发奠定了坚实基础,有望为特应性皮炎患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10